Updated Jul 16, 2026
Gilson Michelle has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $5.03M.
Michelle Gilson is the Chief Financial Officer at Arcellx, Inc., a clinical-stage biotechnology company focused on developing immunotherapies for cancer and other diseases. She has been involved in the company's financial operations and strategic planning.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-28 | ACLX | Arcellx, Inc. | J — Other acquisition / disposition | 5.0K | — | |
| 2026-04-28 | ACLX | Arcellx, Inc. | J — Other acquisition / disposition | 67.0K | — | |
| 2026-04-17 | ACLX | Arcellx, Inc. | M — Option exercise | 2.1K | $8.66 | $18K |
| 2026-04-17 | ACLX | Arcellx, Inc. | M — Option exercise | 36.0K | $8.66 | $312K |
| 2026-03-19 | ACLX | Arcellx, Inc. | G — Bona-fide gift | 5.0K | $0.00 | |
| 2026-02-26 | ACLX | Arcellx, Inc. | S — Open-market sale | 11.2K | $113.82 | $1.28M |
| 2026-02-26 | ACLX | Arcellx, Inc. | M — Option exercise | 20.5K | $0.00 | |
| 2026-02-19 | ACLX | Arcellx, Inc. | S — Open-market sale | 100 | $69.38 | $7K |
| 2026-02-19 | ACLX | Arcellx, Inc. | S — Open-market sale | 5.4K | $68.57 | $371K |
| 2026-02-19 | ACLX | Arcellx, Inc. | S — Open-market sale | 2.9K | $67.73 | $195K |
| 2026-02-19 | ACLX | Arcellx, Inc. | M — Option exercise | 15.3K | $0.00 | |
| 2026-02-18 | ACLX | Arcellx, Inc. | S — Open-market sale | 4.2K | $70.01 | $291K |
| 2026-02-18 | ACLX | Arcellx, Inc. | S — Open-market sale | 7.1K | $69.21 | $494K |
| 2026-02-18 | ACLX | Arcellx, Inc. | M — Option exercise | 20.5K | $0.00 | |
| 2026-01-07 | ACLX | Arcellx, Inc. | M — Option exercise | 20.5K | $0.00 | |
| 2026-01-07 | ACLX | Arcellx, Inc. | M — Option exercise | 15.3K | $0.00 | |
| 2026-01-07 | ACLX | Arcellx, Inc. | M — Option exercise | 20.5K | $0.00 | |
| 2025-10-15 | ACLX | Arcellx, Inc. | S — Open-market sale | 5.4K | $91.04 | $488K |
| 2025-10-03 | ACLX | Arcellx, Inc. | S — Open-market sale | 1.1K | $86.22 | $92K |
| 2025-10-03 | ACLX | Arcellx, Inc. | S — Open-market sale | 4.9K | $86.00 | $420K |
Michelle Gilson is the Chief Financial Officer at Arcellx, Inc., a clinical-stage biotechnology company focused on developing immunotherapies for cancer and other diseases. She has been involved in the company's financial operations and strategic planning.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 16 open-market sales ($5.03M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Gilson Michelle profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.